Listen and follow our podcasts on:

This educational programme is supported by an Independent Medical Education Grant from AstraZeneca

Escuche el Episodio 2 - El potencial de los inhibidores de PARP en el cáncer de próstata: lo que las enfermeras deben saber


El potencial de los inhibidores de PARP en el cáncer de próstata: lo que las enfermeras deben saber (Episodio 2 de 3)

En este episodio, Pablo Peinado y la Dra. Elena Castro analizan los inhibidores de PARP, cómo funcionan, revisan los datos clave de los ensayos, cómo seleccionar los PARPi para sus pacientes con cáncer de próstata y dónde encajan en la secuencia general del tratamiento, además de brindar información sobre la comunicación con los pacientes, los PARPi que actualmente se encuentran en una etapa avanzada de desarrollo y el posible uso futuro de PARPi en combinación con inmunoterapias o inhibidores de la vía del receptor de andrógenos.

En el Episodio 1, Pruebas genéticas e inhibidores de PARP en el cáncer de próstata, Joanne Chien y el Dr. Alexander Wyatt analizan las alteraciones genéticas en el cáncer de próstata y por qué debemos considerar las pruebas genéticas al pensar en opciones de tratamiento como los inhibidores de PARP (PARPi). La discusión cubre por qué se deben realizar pruebas genéticas, quién debe someterse a las pruebas, cómo realizar las pruebas y qué significa esto en relación con el tratamiento con inhibidores de PARP.

El Dr. Alexander Wyatt explica la diferencia entre las mutaciones somáticas y de la línea germinal y Joanne Chien analiza el papel de la enfermera durante las discusiones de asesoramiento genético y cómo este papel puede evolucionar en el futuro. Finalmente, también se consideran los ensayos en curso de inhibidores de PARP en combinación con otros tratamientos para el cáncer de próstata y si es probable que el resultado de estos ensayos afecte a la necesidad de realizar pruebas genéticas.

En el tercer y último episodio, Inhibidores de PARP en el cáncer de próstata: manejo de eventos adversos y la importancia de la comunicación con los pacientes, el Dr. Jason Alcorn y la Dra. Alicia Morgans analizan los eventos adversos asociados con los inhibidores de PARP y el manejo de los mismos, en particular trombocitopenia, efectos gastrointestinales y fatiga. Jason proporciona información sobre cómo las enfermeras apoyan y se comunican con los pacientes, la importancia de la notificación temprana de los efectos secundarios y cómo manejarlos. Finalmente, también se consideran los ensayos en curso de inhibidores de PARP en combinación con otros tratamientos para el cáncer de próstata y lo que estos ensayos pueden significar para los pacientes.

 

Este podcast GU NURSES CONNECT también está disponible en

Castos, Spotify, Podcasts de Apple y Podcasts de Google

Pablo Peinado is a Senior Research Nurse Coordinator at Hospital Universitario Virgen de la Victoria in Malaga, Spain.  Pablo gained his Nursing Degree at the University of Valencia in 2014 and moved to the UK where he worked as a surgical nurse for two years.  In 2016 he received his Clinical Trials master’s degree and started to work as a Haematology Research Nurse at Churchill Hospital, Oxford where he was in charge of conducting different clinical trials for haematology patients. Pablo moved back to Spain in 2017 to be part of a new GU tumour unit under Dr David Olmos at Hospital Virgen de la Victoria, Malaga and worked as an Oncology Research Nurse with GU patients diagnosed with prostate, bladder and kidney cancer, coordinating early and late phase clinical trials.  He has recently been promoted to lead a new Clinical Research Unit and is in charge of coordinating a unit where the objectives are to treat patients with the most advanced medications and provide a personalised approach to their disease so that they can participate more actively during their treatment, learning about their disease and understanding the process of their treatment.

Dr Elena Castro is a Consultant Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, Spain.  She treats patients with advanced bladder and prostate cancer, most of them within the context of clinical trials. She studied medicine and obtained a PhD from the University of Salamanca, Spain.  After training in medical oncology, she completed a four-year fellowship in Cancer Genetics at the Institute of Cancer Research, UK.   Later, she joined the Spanish National Cancer Research Center as a clinician-scientist.  Her research has focused on addressing the clinical implications of genetic and genomic variants in prostate cancer, receiving several awards for her work. She has also authored numerous articles published in international peer-reviewed journals including some relevant papers on the impact of germline variants in prostate cancer.   

Dr Elena Castro has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Janssen, MSD, Novartis, Pfizer, Synlab and Telix. 

The potential of PARP inhibitors in prostate cancer: What nurses need to know

Episode

2

of

episodes
GU NURSES CONNECT
Experts
Dr Elena Castro, Pablo Peinado
Endorsed By
Urobel VZW | ASBL
  • download Downloadable
    Resouces
  • clock 25 MIN
  • calendar Jan 2022
  • EACCME
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
Programme summary
  • clock Duration 25 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
interactive-patient-case Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
other Other
Oncology 
Lung cancer survey: Patient views on biomarker testing

Share the survey with patients with lung cancer and their caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
podcast Podcast
Oncology 
Precision oncology approaches in lung cancer

Explore pre-analytical phase challenges and biomarker testing in lung cancer. Moderated by the Oncology Brothers.

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.